Insilico Medicine Secures $110 Million Series E Financing to Advance AI-Driven Drug Discovery Innovation
- Editor
- Mar 13
- 1 min read
Whats Happening:
Insilico Medicine, a clinical-stage AI-driven drug discovery company, has secured $110 million in Series E financing. The round was led by Value Partners Group, with participation from new industry- and technology-focused investors and existing backers. The funds will be used to advance Insilico's drug pipeline and AI platform developments, including refining AI models and algorithms, expanding its automatic lab, and accelerating clinical validation of its flagship candidate for idiopathic pulmonary fibrosis treatment.
Key Moves:
Insilico Medicine raises $110 million in Series E financing
Funds to be used for advancing drug pipeline and AI platform developments
Focus on clinical validation of flagship candidate for idiopathic pulmonary fibrosis
By The Numbers:
Insilico has reduced average time to PCC nomination to 12-18 months
Company has built a portfolio of 30 assets with 10 receiving IND clearance
Secured over $2.1 billion in out-licensing deals and $1.4 billion in collaborations
Key Quotes:
"We are thrilled to announce our $110 million Series E financing—a key milestone that reflects our unwavering commitment to transforming healthcare and the strong confidence of our investors," said Alex Zhavoronkov, PhD, Founder and CEO of Insilico Medicine.
"We believe that Insilico's advancements will not only accelerate the development of life-saving therapies but also redefine the future of biopharmaceutical R&D," said Dr. Chuen Yan Leung, Partner (Healthcare Investments) at Value Partners Group.
Bottom Line:
Insilico Medicine's successful $110 million Series E financing demonstrates strong investor confidence in AI-driven drug discovery. The fund will accelerate the company's innovative drug pipeline and AI platform developments, potentially transforming the biopharmaceutical R&D landscape and accelerating the development of life-saving therapies.
Comments